EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

Einmal wöchentliches Somapacitan als Alternative zur Behandlung des Wachstumshormonmangels bei präpubertären Kindern: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien

Ghina Tsurayya iD, Cut Alifiya Nazhifah iD, Muhammad Rahmat Pirwanja iD, Putri Oktaviani Zulfa, Muhammad Raihan Ramadhan Tatroman, Fajar Fakri iD, Muhammad Iqhrammullah iD

Children · 09.02.2024 · 11 (2) · 227

DOI: 10.3390/children11020227 ↗

Auf einen Blick

Sechs Studien sprechen dafür, dass Somapacitan einmal wöchentlich eine ähnliche Wirksamkeit und Sicherheit wie tägliche Wachstumshormone hat. Die Adhärenz war unter Somapacitan höher.

Fragestellung

Wie wirksam, sicher und adherent ist einmal wöchentliches subkutanes Somapacitan im Vergleich zu täglichem Wachstumshormon bei präpubertären Kindern mit GHD?

Methode

Systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien; Suche in PubMed, Embase und Scopus bis 17. Oktober 2023.

Ergebnisse

6 Studien in der systematischen Übersicht, 2 Studien in der gepoolten Analyse. Wirksamkeit ähnlich: HV MD 0,04; HV SDs MD −0,71; Height SDs MD 0,11; IGF-I SDs MD 0,06; BA vs. CA MD 0,67. Adhärenz höher: OR 3,02; 95 %-KI fehlt.

Einschränkungen

Nur 2 der 6 eingeschlossenen Studien waren für die gepoolte Analyse geeignet.

Schlussfolgerung der Autor:innen

Somapacitan hatte eine ähnliche Wirksamkeits- und Sicherheitsbilanz wie tägliche Wachstumshormone; die geringere Injektionsfrequenz führte zu besserer Adhärenz.

Kernaussagen

  • Wirksamkeit von Somapacitan und täglichem Wachstumshormon ähnlich
  • Adhärenz unter Somapacitan höher (OR 3,02)
  • Disease-burden-Scores ebenfalls ähnlich

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Children, online erschienen am 09.02.2024. Verfasst von Ghina Tsurayya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Growth hormone treatment has effectively restored normal growth in children with growth hormone deficiency (GHD); however, it poses challenges in compliance with a daily growth hormone injection regimen, leading to low adherence and persistence rates. Once-weekly Somapacitan is a potential alternative for treating children with GHD. This study aimed to evaluate the efficacy, safety, and adherence of once-weekly subcutaneous Somapacitan compared to daily growth hormone injection in prepubertal children with GHD. A search for the published records was carried out on 17 October 2023 utilizing the searching feature available on PubMed, Embase, and Scopus. Primary study outcomes included (1) efficacy, measured by height velocity (HV), standard deviation score (SDs), height SDs, insulin-like growth factor-SDs (IGF-I SDs), and bone age vs. chronological age ratio (BA vs. CA); (2) safety, assessed through adverse events and injection site reactions; and (3) adherence, determined by the percentage of the sample completing treatments. Secondary outcomes evaluated disease burden scores, divided into three subgroup domains: emotional well-being, physical functional, and social well-being scores. We retrieved 6 studies that were eligible for the systematic review (417 versus 186 for intervention and control, respectively). Only 2 of the total included studies were eligible for pooled analysis (175 versus 82 for intervention and control, respectively). The efficacy profile of Somapacitan was similar to daily growth hormones, indicated by HV (mean difference (MD = 0.04; p = 0.96), HV SDs (MD = −0.71; p = 0.09), height SDs (MD = 0.11; p = 0.69), IGF-I SDs (MD = 0.06; p = 0.70), and CA vs. BA (MD = 0.67; p = 0.70)), demonstrated similar and non-inferior outcomes. Treatment adherence is 3 times higher in the Somapacitan group as compared to control (OR = 3.02; p = 0.03) with adherence rates reaching 95% and 88% for Somapacitan and Norditropin®, respectively. The disease burden measurement is similar in Somapacitan and daily growth hormones (MD = −0.62; p = 0.83), as indicated by the Growth Hormone Deficiency–Child Impact Measure. In almost all outcomes, the level of confidence is strong. The confidence level in the data is generally strong, but for CA vs. BA and the subgroup of severe adverse events with heterogeneity >50%, the confidence level is moderate. Although the efficacy and safety profiles of Somapacitan were found to be similar to those of daily growth hormones, a reduced frequency of once-weekly Somapacitan injections led to increased adherence. PROSPERO registration: CRD42023473209.

Schlagwörter

Stichwörter der Autor:innen

GHDNorditropinSomapacitangrowth hormoneinsulin-like growth factor-1

Autor:innen und Institutionen

  • Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia.
  • Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia.
  • Postgraduate Program of Public Health, Universitas Muhammadiyah Aceh, Banda Aceh 23123, Indonesia.

ORCID-Profile: Ghina Tsurayya, Cut Alifiya Nazhifah, Muhammad Rahmat Pirwanja, Fajar Fakri, Muhammad Iqhrammullah

Zitieren

APA

Tsurayya, G., Nazhifah, C. A., Pirwanja, M. R., Zulfa, P. O., Tatroman, M. R. R., Fakri, F., & Iqhrammullah, M. (2024). Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Children, 11(2), 227. https://doi.org/10.3390/children11020227

Vancouver

Tsurayya G, Nazhifah CA, Pirwanja MR, Zulfa PO, Tatroman MRR, Fakri F, et al. Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Children. 2024;11(2):227. doi:10.3390/children11020227

BibTeX
@article{Tsurayya2024,
  author = {Tsurayya, Ghina and Nazhifah, Cut Alifiya and Pirwanja, Muhammad Rahmat and Zulfa, Putri Oktaviani and Tatroman, Muhammad Raihan Ramadhan and Fakri, Fajar and Iqhrammullah, Muhammad},
  title = {Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial},
  journal = {Children},
  year = {2024},
  volume = {11},
  number = {2},
  pages = {227},
  doi = {10.3390/children11020227}
}
Kostenlos starten →